BLOOD CANCER AWARENESS MONTH
The Lymphoma Research Foundation’s mission is to eradicate lymphoma and serve those impacted by this blood cancer.
The Lymphoma Research Foundation funds research with the greatest ability to impact lives
and empowers patients and their loved ones to be their best health advocates.
Accelerate the pace of lymphoma research.
Lu, WM Survivor ›
“The tremendous outpouring of compassion from all of those around me became the ‘gift’ of cancer which sustained me with much gratitude.”
Marian, HL Survivor ›
“The day I rang the bell after receiving a clean bill of health made me feel like a butterfly that had finally broken out of her cocoon to take flight.”
Bob, MCL Survivor ›
“When I meet other MCL patients, survivors, and caregivers I tell them that I’m a 19-year survivor and there is hope at the end of the tunnel.”
09/14/2021 | On September 14, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.